✦ LIBER ✦

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors

✍ Scribed by Sun, Jong-Mu; Ahn, Myung-Ju; Choi, Yoon-La; Ahn, Jin Seok; Park, Keunchil

Book ID: 123559662
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 590 KB
Volume: 82
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2013.08.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The EGFR T790M Mutation in Acquired Resi

The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

✍ Kim, Y.; Ko, J.; Cui, Z.; Abolhoda, A.; Ahn, J. S.; Ou, S.-H.; Ahn, M.-J.; Park, 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 911 KB

Mechanisms of acquired resistance to EGF

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

✍ Ji, Wonjun; Choi, Chang-Min; Rho, Jin; Jang, Se; Park, Young; Chun, Sung-Min; Ki 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 506 KB

Pretreatment Epidermal Growth Factor Rec

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer

✍ Su, K.-Y.; Chen, H.-Y.; Li, K.-C.; Kuo, M.-L.; Yang, J. C.-H.; Chan, W.-K.; Ho, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 676 KB

Disease Flare after Tyrosine Kinase Inhi

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

✍ Chaft, J. E.; Oxnard, G. R.; Sima, C. S.; Kris, M. G.; Miller, V. A.; Riely, G. 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 338 KB

Activating and resistance mutations of E

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

✍ Gazdar, A F 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 213 KB

Mutation abundance affects the efficacy

Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance

✍ Zhao, Ze-Rui; Wang, Jin-Feng; Lin, Yong-Bin; Wang, Fang; Fu, Sha; Zhang, Shu-Lin 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 328 KB